Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Innate Pharma SA ( (FR:IPH) ) has provided an announcement.
On April 30, 2025, Innate Pharma announced the filing of its 2024 Universal Registration Document with the French market authority and its annual report on Form 20-F with the U.S. SEC. These filings mark a significant step in maintaining regulatory compliance and transparency, potentially impacting the company’s operations and stakeholder confidence. The filings provide detailed insights into Innate Pharma’s financial and operational performance for 2024, reinforcing its position in the biotechnology industry.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes innovative approaches to harness the innate immune system through three therapeutic strategies: multi-specific NK Cell Engagers via its ANKET® platform, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca to advance research and development.
YTD Price Performance: -50.0%
Average Trading Volume: 1,075
Technical Sentiment Signal: Buy
Current Market Cap: $174.5M
For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.